You are here

Article Text

Article menu
Download PDFPDF
Short report
Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease
  1. Oliver Stich,
  2. Barbara Kleer,
  3. Sebastian Rauer
  1. Neurologische Klinik und Poliklinik der Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany
  1. Correspondence to:
 Professor Sebastian Rauer
 Neurologische Klinik und Poliklinik der Albert-Ludwigs-Universitaet Freiburg, Breisacher Strasse 64, D-79106 Freiburg, Germany; sebastian.rauer{at}uniklinik-freiburg.de

Abstract

Background: Well characterised antineuronal antibodies (ANAbs) have been shown to be highly specific markers of neurological syndromes with a paraneoplastic aetiology. Previous reports indicate that pure motor neuron disease (MND) is rarely of paraneoplastic origin.

Objective: To screen systematically for the prevalence of well characterised paraneoplastic ANAbs in a large collective of patients with pure MND.

Methods: In a cohort of 145 patients with MND, the frequency of ANAbs was estimated by ELISA, employing recombinant antigens (HuD, Yo, Ri, CV2/CRMP5, Ma2 and amphiphysin).

Results: None of the sera revealed high antineuronal antigen reactivity. Very low reactivity was detected in only five sera, in all probability representing background activity.

Conclusion: According to these data, routine analysis for ANAbs in patients with isolated MND is not mandatory.

  • ALS, amyotrophic lateral sclerosis
  • ANAbs, antineuronal antibodies
  • LMN, lower motor neuron
  • MND, motor neuron disease
  • OD, optical density
  • PNS, paraneoplastic neurological syndromes

http://dx.doi.org/10.1136/jnnp.2006.097774

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Published Online First 21 February 2007

    • Ravo Diagnostika GmbH provided the recombinant antigens for this study.

    • Competing interests: S Rauer is a founding executive board member of Ravo Diagnostika GmbH, Freiburg, Germany.